Introducing HaNTr – Halloysite Nanotubes Targeting System for The Selective Delivery of Antibiotics
Source abstract
Abstract
Abstract Antibiotics have been established to induce indiscriminate detrimental effects on the gut commensal bacteria which are vital for human health. This study unprecedently reports the mitigation of this challenge through the targeted delivery of antibiotics to a specific intestinal model pathogen using naturally occurring nanoclay. The designed Halloysite nanotubes targeting (HaNTr) system employs intrinsically mesoporous clay particles, functionalized with antibodies against Escherichia coli (E. coli). Loaded with the antibiotic ciprofloxacin (CIP), the HaNTr particles demonstrate enhanced selectivity of their payload in a human microbiome ex vivo system, preserving the composition of non‐target populations. Furthermore, the HaNTr system exhibits up to a 10‐fold increase in selectivity against E. coli, compared to neat CIP, in a heterogenous culture. This enhanced selectivity is attributed to the sustained and localized release of CIP from the HaNTr particles (≈0.8 ng CIP min−1 mg−1), following their specific binding to target bacteria, as quantitatively measured by high‐throughput imaging flow cytometry. Importantly, HaNTr particles are also shown to be biocompatible with Caco‐2 cells, mimicking the intestinal epithelium. This work highlights the prominent capability of the HaNTr system in alleviating antibiotic‐associated dysbiosis by the targeted delivery of antimicrobials to potentially any microorganism against which the immobilized capture probe can be customized.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Clay minerals and soil interactions · Therapeutic Uses of Natural Elements · Pharmacological Effects and Toxicity Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biotechnology and Food Engineering Technion – Israel Institute of Technology Technion City Haifa 3200003 Israel
The Russel Berrie Nanotechnology Institute Technion – Israel Institute of Technology Technion City Haifa 3200003 Israel
References (87)
Show source-provided references
1. P.charitable Trusts Report: The Critical Need for New Antibiotics 2018.
2. J.O'Neill Report: Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations – The Review on Antimicrobial Resistance 2014.
3. 10.1016/S0140-6736(22)02185-710.1016/S0140-6736(22)02185-7 ↗
4. 10.1177/2049936123115444310.1177/20499361231154443 ↗
5. 10.1038/nri.2017.710.1038/nri.2017.7 ↗
6. 10.3389/fcimb.2020.57291210.3389/fcimb.2020.572912 ↗
7. 10.1038/s41392-022-00974-410.1038/s41392-022-00974-4 ↗
8. 10.1002/mbo3.126010.1002/mbo3.1260 ↗
9. 10.1186/s12967-022-03296-910.1186/s12967-022-03296-9 ↗
10. 10.1016/j.cell.2018.08.04710.1016/j.cell.2018.08.047 ↗
11. 10.1016/j.jconrel.2011.07.00210.1016/j.jconrel.2011.07.002 ↗
12. 10.1039/D0MD00347F10.1039/D0MD00347F ↗
13. 10.1039/C4TB01110D10.1039/C4TB01110D ↗
14. 10.1002/adfm.20221515310.1002/adfm.202215153 ↗
15. 10.1021/acsinfecdis.2c0001710.1021/acsinfecdis.2c00017 ↗
16. 10.1016/j.ijpharm.2023.12296710.1016/j.ijpharm.2023.122967 ↗
17. Muguruza A. R. · Nanoscale Adv. · 2023
18. 10.1021/am403940d10.1021/am403940d ↗
19. 10.1038/s41551-017-0187-510.1038/s41551-017-0187-5 ↗
20. 10.1002/adma.20170152710.1002/adma.201701527 ↗
21. 10.1021/acs.biomac.1c0008210.1021/acs.biomac.1c00082 ↗
22. 10.1007/s11274-020-02845-y10.1007/s11274-020-02845-y ↗
23. 10.3389/fbioe.2023.116679010.3389/fbioe.2023.1166790 ↗
24. 10.1039/D0NR06820A10.1039/D0NR06820A ↗
25. Dube S. · Adv. Colloid Interface Sci. · 2022 · 309
26. 10.3390/nano905070810.3390/nano9050708 ↗
27. 10.1016/j.clay.2022.10662910.1016/j.clay.2022.106629 ↗
28. 10.1021/acsami.9b0749910.1021/acsami.9b07499 ↗
29. 10.1039/D1RA07821F10.1039/D1RA07821F ↗
30. 10.1002/adma.20150234110.1002/adma.201502341 ↗
31. Joussein E. · 2016 · 12
32. Yang H. · 2016 · 67
33. 10.1016/j.cis.2018.05.00710.1016/j.cis.2018.05.007 ↗
34. 10.3390/molecules2520486310.3390/molecules25204863 ↗
35. 10.1038/nbt0787-69710.1038/nbt0787-697 ↗
36. 10.1039/D0AN00178C10.1039/D0AN00178C ↗
37. 10.1021/acsabm.0c0133210.1021/acsabm.0c01332 ↗
38. 10.3390/pharmaceutics1410209410.3390/pharmaceutics14102094 ↗
39. 10.1016/j.ejmech.2018.01.07810.1016/j.ejmech.2018.01.078 ↗
40. 10.1016/B978-0-12-386454-3.00011-710.1016/B978-0-12-386454-3.00011-7 ↗
41. 10.1128/AAC.28.4.58110.1128/AAC.28.4.581 ↗
42. 10.2147/IDR.S34864310.2147/IDR.S348643 ↗
43. 10.1186/1752-1947-4-11110.1186/1752-1947-4-111 ↗
44. 10.1093/jac/46.suppl_1.4110.1093/jac/46.suppl_1.41 ↗
45. 10.1093/jac/dky53010.1093/jac/dky530 ↗
46. 10.3389/fmicb.2021.76703810.3389/fmicb.2021.767038 ↗
47. 10.1016/j.colsurfa.2012.12.04810.1016/j.colsurfa.2012.12.048 ↗
48. 10.1016/j.apsusc.2017.06.10410.1016/j.apsusc.2017.06.104 ↗
49. 10.1039/C5RA04444H10.1039/C5RA04444H ↗
50. Iangone J. J. · 1982 · 157
51. 10.1002/aocs.1219610.1002/aocs.12196 ↗
52. 10.1016/j.clay.2017.10.00210.1016/j.clay.2017.10.002 ↗
53. 10.1007/s10565-005-0085-610.1007/s10565-005-0085-6 ↗
54. 10.1128/CMR.19.2.315-337.200610.1128/CMR.19.2.315-337.2006 ↗
55. Baudry‐Simner P. J. · Can. J. Infect. Dis. Med. Microbiol. · 2012 · 23
56. 10.1016/j.carbpol.2018.05.07110.1016/j.carbpol.2018.05.071 ↗
57. 10.1016/j.progpolymsci.2013.05.00910.1016/j.progpolymsci.2013.05.009 ↗
58. 10.1038/s41578-023-00552-210.1038/s41578-023-00552-2 ↗
59. 10.1021/acsami.8b1753310.1021/acsami.8b17533 ↗
60. Choi H. J. · Journal of Nanoparticle Research. · 2008
61. 10.4161/19490976.2014.97222310.4161/19490976.2014.972223 ↗
62. 10.1007/s00203-015-1135-y10.1007/s00203-015-1135-y ↗
63. 10.1016/j.matlet.2016.05.10810.1016/j.matlet.2016.05.108 ↗
64. 10.1007/s00253-018-8880-110.1007/s00253-018-8880-1 ↗
65. 10.1016/j.jconrel.2007.12.01110.1016/j.jconrel.2007.12.011 ↗
66. 10.1038/s41586-021-03986-210.1038/s41586-021-03986-2 ↗
67. 10.1016/j.tifs.2016.10.01710.1016/j.tifs.2016.10.017 ↗
68. 10.1073/pnas.100008710710.1073/pnas.1000087107 ↗
69. 10.1016/j.fufo.2022.10019710.1016/j.fufo.2022.100197 ↗
70. 10.1186/s40168-018-0538-910.1186/s40168-018-0538-9 ↗
71. Davies M. · Gut Microbes. · 2022 · 14
72. 10.1016/j.jinf.2019.10.00810.1016/j.jinf.2019.10.008 ↗
73. Baeckmann C. · Adv. Mater. Interfaces. · 2022 · 9
74. 10.1080/00319104.2015.107404610.1080/00319104.2015.1074046 ↗
75. 10.1007/978-1-4939-7834-2_710.1007/978-1-4939-7834-2_7 ↗
76. 10.1111/tan.1207110.1111/tan.12071 ↗
77. 10.1093/bioinformatics/btt59310.1093/bioinformatics/btt593 ↗
78. 10.14806/ej.17.1.20010.14806/ej.17.1.200 ↗
79. 10.1093/bioinformatics/btq46110.1093/bioinformatics/btq461 ↗
80. 10.1016/j.jbiotec.2017.06.119810.1016/j.jbiotec.2017.06.1198 ↗
81. 10.1038/nmeth.386910.1038/nmeth.3869 ↗
82. 10.1093/nar/gks04210.1093/nar/gks042 ↗
83. R.Core Team R: A language and environment for statistical computing 2018.
84. 10.1093/bioinformatics/btp61610.1093/bioinformatics/btp616 ↗
85. 10.1111/j.2517-6161.1995.tb02031.x10.1111/j.2517-6161.1995.tb02031.x ↗
86. Oksanen J. · Community Ecology Package. · 2013
87. 10.1007/978-0-387-98141-310.1007/978-0-387-98141-3 ↗